Rare Case of Endoscopic Treatment for Bevacizumab-Related Gastric Perforation in a Patient with Ovarian Cancer

被引：1
|
作者：
Cappuccio, Serena [1 ]
Marinucci, Benito [2 ]
Bove, Vincenzo [3 ]
Turco, Luigi Carlo [4 ,5 ]
Cosentino, Francesco [5 ]
Scambia, Giovanni [1 ,2 ]
Costamagna, Guido [2 ,3 ]
Boskoski, Ivo [2 ,3 ]
机构：
[1] Fdn Policlin Univ A Gemelli IRCCS, Dept Womans Childs & Publ Hlth, Rome, Italy
[2] Univ Cattolica Sacro Cuore, Fac Med & Chirurg, Rome, Italy
[3] Fdn Policlin Univ Agostino Gemelli IRCCS, Digest Endoscopy Unit, Rome, Italy
[4] Mater Olbia Spa, Gynecol & Breast Care Unit, Olbia, Italy
[5] Univ Cattolica Sacro Cuore, Gynecol Oncol, Gemelli Molise Spa, Campobasso, Italy
来源：
CHEMOTHERAPY | 2020年 / 65卷 / 1-2期
关键词：
Adverse events; Bevacizumab; Endoscopic suture; Gastric perforation; Ovarian cancer; GASTROINTESTINAL PERFORATION; PHASE-3; TRIAL; CHEMOTHERAPY; THERAPY; RISK; COMBINATION; FOCUS;
D O I：
10.1159/000508556
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Antiangiogenic chemotherapy is a common treatment option for patients with advanced ovarian cancer (OC) and has been proven to be effective and generally safe. Nevertheless, in rare cases, these drugs can give serious complications such as gastrointestinal perforations that can be even mortal or very difficult to treat and can heavily impact the clinical management. We present a rare case of bevacizumab-induced gastric perforation in a patient with advanced OC occurred during bevacizumab-including chemotherapy in an adjuvant setting. Surgical treatment was not possible due to the frailty of the clinical condition of the patient and the gastric perforation was successfully treated with endoscopic suturing.
引用
收藏
页码：54 / 57
页数：4
相关论文
共 50 条
  • [1] Gastric Perforation Presenting as Empyema in a Patient with Pancreatic Cancer on Bevacizumab Treatment
    Shao, Yu-Yun
    Lin, Zhong-Zhe
    Liang, Po-Chin
    Tien, Yu-Wen
    Cheng, Ann-Lii
    ANTICANCER RESEARCH, 2009, 29 (05) : 1665 - 1667
  • [2] Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer
    Sasaki, Akinori
    Harano, Kenichi
    Kogawa, Takahiro
    Matsubara, Nobuaki
    Naito, Yoichi
    Hosono, Ako
    Mukai, Hirofumi
    Yoshino, Takayuki
    Mukohara, Toru
    CASE REPORTS IN ONCOLOGICAL MEDICINE, 2020, 2020
  • [3] A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants
    Maluf, Gustavo
    Caldas, Rogerio Jardim
    Fregnani, Eduardo Rodrigues
    da Silva Santos, Paulo Sergio
    INTERNATIONAL JOURNAL OF IMPLANT DENTISTRY, 2019, 5 (01)
  • [4] Bladder perforation in a patient with recurrent epithelial ovarian cancer after treatment with bevacizumab
    Bansal, Nisha
    Hoffman, Mitchell
    GYNECOLOGIC ONCOLOGY, 2011, 120 (02) : 313 - 314
  • [5] A rare case of pneumatosis intestinalis after gastrocystostomy in an ovarian cancer patient under bevacizumab treatment
    Michaan, Nadav
    Kim, Sun Ho
    Park, Sang Yoon
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2019, 40 (01) : 157 - 159
  • [6] A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants
    Gustavo Maluf
    Rogério Jardim Caldas
    Eduardo Rodrigues Fregnani
    Paulo Sérgio da Silva Santos
    International Journal of Implant Dentistry, 5
  • [7] Incidence and management of bevacizumab-related toxicities in colorectal cancer
    Saif, M. Wasif
    Mehra, Ranee
    EXPERT OPINION ON DRUG SAFETY, 2006, 5 (04) : 553 - 566
  • [8] Cost Effectiveness of Alternative Strategies for Incorporating Bevacizumab Into the Primary Treatment of Ovarian Cancer
    Barnett, Jason C.
    Secord, Angeles Alvarez
    Cohn, David E.
    Leath, Charles A., III
    Myers, Evan R.
    Havrilesky, Laura J.
    CANCER, 2013, 119 (20) : 3653 - 3661
  • [9] The roles and limitations of bevacizumab in the treatment of ovarian cancer
    Nakai, Hidekatsu
    Matsumura, Noriomi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (07) : 1120 - 1126
  • [10] Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients
    De Stefano, Alfonso
    Carlomagno, Chiara
    Pepe, Stefano
    Bianco, Roberto
    De Placido, Sabino
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (05) : 1207 - 1213
12345